Wet age-related macular degeneration (wAMD) is the leading cause of irreversible vision loss in people older than 50 years of age in Western countries. Given the crucial role of vascular endothelial growth factor (VEGF) in the pathogenesis of wAMD, anti-VEGF drugs currently represent the first-line treatment option in the management of the disease. Among the novel anti-VEGF agents investigated, brolucizumab is a single-chain antibody fragment inhibiting all isoforms of VEGF-A. In this regard, the phase III HAWK and HARRIER trials have shown promising results of brolucizumab in terms of clinical efficacy and safety for treating wAMD. In this review, we will discuss brolucizumab's pharmacokinetics, pharmacodynamics and clinical efficacy, focusing also on its safety and tolerability profile.
Brolucizumab: USAN; Rec INN
Ferro Desideri L.;Barra F.;Ferrero S.
2019-01-01
Abstract
Wet age-related macular degeneration (wAMD) is the leading cause of irreversible vision loss in people older than 50 years of age in Western countries. Given the crucial role of vascular endothelial growth factor (VEGF) in the pathogenesis of wAMD, anti-VEGF drugs currently represent the first-line treatment option in the management of the disease. Among the novel anti-VEGF agents investigated, brolucizumab is a single-chain antibody fragment inhibiting all isoforms of VEGF-A. In this regard, the phase III HAWK and HARRIER trials have shown promising results of brolucizumab in terms of clinical efficacy and safety for treating wAMD. In this review, we will discuss brolucizumab's pharmacokinetics, pharmacodynamics and clinical efficacy, focusing also on its safety and tolerability profile.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
